A drug efficacy evaluation model for diabetic nephropathy developed in collaboration with Japan's Clea and Physiogenex. It shows significant renal damage pathologically at 17 weeks of age.
We are developing a pharmacological evaluation model for diabetic nephropathy using the type 2 diabetes model SDT fatty rat. Currently, it has been clarified that unilateral nephrectomy and salt loading in drinking water (for 10 weeks) lead to the manifestation of diabetic nephropathy at an early age of 17 weeks. After several trials, we are still continuing our investigations as of 2017. The main data published by June 2017 are as follows: - The SDT fatty rats subjected to unilateral nephrectomy and salt loading show a decrease in GFR to below 50% at 17 weeks of age, presenting significant renal impairment. - Administration of the SGLT2 inhibitor Dapagliflozin for 10 weeks demonstrates an inhibitory effect on the progression of renal complications in SDT fatty rats subjected to unilateral nephrectomy and 0.3% saline loading. *Inquiries can also be made through our company website. We will respond promptly. (Search for "Clea Japan" at http://www.clea-japan.com/)
Inquire About This Product
basic information
Example: Composition of 3 groups (n=10) Group 1 is the control, and groups 2 and 3 receive the test compounds (multiple drugs (combination) or multiple dosage levels) Protocol Overview: (For details, please contact us) - Acclimatization period of 2 weeks for 4-week-old male mice - Unilateral nephrectomy at 6 weeks of age, followed by a 1-week recovery period, and random grouping based on creatinine clearance and blood glucose levels. - 0.3% salt load starting from 7 weeks of age (for 10 weeks) - Measurable parameters: HbA1c, blood glucose levels during fed and fasting states, plasma insulin, plasma urea, urinary albumin, creatinine clearance, and GFR (FITC-inulin) will be measured 4 times (at 5, 7, 12, and 17 weeks of age) *Inquiries can also be made through our website. We will respond promptly. (Search for "Clea Japan" http://www.clea-japan.com/)
Price range
Delivery Time
※Approximately 6 months from the exam period to the final report.
Applications/Examples of results
Latest Academic Presentation Kidney Week (November 3, 2017) ISN Frontier (February 23, 2017) Keystone Symposia Conference (February 26, 2018) Title Dapagliflozin Alone or Combined with Ramipril Improves Hyperglycemia, Hypertension, and Prevents Kidney Complications and GFR Decline in the Nephrectomized SDT Fatty Rat Model of Diabetic Nephropathy. Summary Administration of SGLT2 inhibitors shows improvement in kidney complications, and combination therapy with ACE inhibitors delays the decline in GFR. *Inquiries can also be made through our website. We will respond promptly. (Search for "Clea Japan" http://www.clea-japan.com/)
Company information
Nihon Kurea Co., Ltd. is a company primarily engaged in the production and sale of laboratory animals, the manufacture and sale of laboratory animal feed, and the manufacture and sale of laboratory animal housing equipment, tools, facilities, and devices. In response to research using laboratory animals, we have been working on the development and improvement of various types of laboratory animal feed. Currently, there are 15 different brands available. These feeds are supplied under strict management from the procurement of raw materials to formulation, manufacturing, product inspection, storage, and transportation, in accordance with the regulations of the "Nihon Kurea Co., Ltd. Business Standards for Management Criteria Related to Laboratory Animal Feed," with the aim of maintaining consistently stable quality and improving reliability.
![★GMP Compliant [Buffer Contract Manufacturing Service]](https://image.mono.ipros.com/public/product/image/28b/2001528046/IPROS11360744701047854026.jpg?w=280&h=280)